In the development of CD44‐targeted antitumor strategy, doxorubicin modified with anti‐CD44mAb exhibited pronounced increase in cellular uptake and elevated intracellular doxorubicin concentration than doxorubicin in CD44‐positive colorectal cancer model [238]. The gene discussed is CD44; the disease is colorectal cancer.